Switching From Liraglutide to Semaglutide or Zepbound: Doses and Gaps
None of the Wegovy, Zepbound, oral semaglutide, or Saxenda labels offers a liraglutide-to-weekly-drug conversion. Wegovy starts at 0.25 mg once weekly for 4 weeks and Zepbound at 2.5 mg once weekly for 4 weeks, and no washout period appears in these labels.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
There is no dose conversion between liraglutide (Saxenda or Victoza) and the weekly GLP-1 drugs in the labels covered here. The prescribing information for Wegovy, Zepbound, and oral semaglutide (Rybelsus and Ozempic tablets) contains no table that equates a liraglutide dose with a semaglutide or tirzepatide dose [2] [3] [4] [5]. Each weekly drug’s label states one starting dose and one titration schedule, and the dosage sections are silent on prior GLP-1 use [2] [3] [4].
For Wegovy injection, the labeled starting dose is 0.25 mg once weekly for 4 weeks [2]. For Zepbound, it is 2.5 mg injected under the skin once weekly for 4 weeks [4]. No washout interval appears in the Saxenda, Wegovy, or Zepbound labels, and all three state that the drugs should not be used together [2] [4] [5]. The timing of the switch is a decision the labels leave to the prescriber. This page is general information about what the labels and studies say, not medical advice.
Is there a liraglutide-to-Wegovy or Ozempic conversion chart?
No. None of the Wegovy, Zepbound, oral semaglutide, or Saxenda labels publishes a dose-equivalence or conversion table between liraglutide and semaglutide or tirzepatide [2] [3] [4] [5]. Any chart claiming “Saxenda 3 mg equals Wegovy X mg” is not coming from those labels.
The only switching instructions that appear in any of these labels are within semaglutide products themselves. The oral semaglutide label (Rybelsus and Ozempic tablets) has sections on switching between Rybelsus and Ozempic tablets, and from Ozempic injection to those tablets [3]. Even there, the label warns that Rybelsus and Ozempic tablets are “not substitutable on a mg-to-mg basis” [3]. That statement applies between the two oral products themselves; no label here extends it into a conversion between different drugs.
STEP 8, the trial comparing weekly semaglutide with daily liraglutide, did not study switching at all. It compared the two drugs in parallel randomized groups — participants were assigned to a treatment rather than moved from one drug to the other mid-trial [1].
What dose does each weekly drug start at?
Each label states one starting dose and one titration schedule, and none of the dosage sections addresses prior GLP-1 use — they neither mandate the standard start for former liraglutide users nor offer an alternate one [2] [3] [4].
| Drug | How it’s taken | Starting dose | Titration | Usual maintenance |
|---|---|---|---|---|
| Wegovy injection | Once weekly under the skin | 0.25 mg for 4 weeks [2] | Every 4 weeks per the label’s escalation table [2] | 2.4 mg once weekly [2] |
| Wegovy tablets | Once daily by mouth | 1.5 mg for 30 days [2] | Every 30 days [2] | 25 mg once daily [2] |
| Zepbound | Once weekly under the skin | 2.5 mg for 4 weeks [4] | 2.5 mg increments after at least 4 weeks [4] | 5, 10, or 15 mg weekly for weight reduction; 10 or 15 mg weekly for obstructive sleep apnea; max 15 mg [4] |
| Ozempic tablets | Once daily by mouth | 1.5 mg days 1–30 [3] | 4 mg days 31–60 [3] | 4 mg, or 9 mg if more glycemic control is needed [3] |
| Rybelsus | Once daily by mouth | 3 mg days 1–30 [3] | 7 mg days 31–60 [3] | 7 mg, or 14 mg if more glycemic control is needed [3] |
Wegovy injection comes in 0.25, 0.5, 1, 1.7, and 2.4 mg single-dose pens and syringes, a 7.2 mg Wegovy HD single-dose pen, and a FlexTouch pen holding 9.6 mg/3 mL that delivers four 2.4 mg doses [2]. For comparison, Saxenda is injected once daily, starting at 0.6 mg per day for one week and increasing at weekly intervals until reaching the recommended 3 mg daily dose [5].
Whether a person coming off liraglutide starts at the labeled starting dose or something else is a prescriber decision. The dosage sections simply do not address prior GLP-1 use [2] [3] [4].
Can I take Saxenda and Wegovy (or Zepbound) together?
No. The labels advise against it. Saxenda’s Limitations of Use states that coadministration with other liraglutide-containing products or any other GLP-1 receptor agonist is not recommended [5]. Wegovy’s label says the same about combining it with other semaglutide products or any other GLP-1 receptor agonist [2]. Zepbound’s label states that coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended [4].
The Limitations of Use text goes no further than “not recommended.”
How long do I need to wait between liraglutide and the new weekly drug?
No washout interval appears in the Saxenda, Wegovy, or Zepbound labeling [2] [4] [5]. There is no waiting period in these labels to cite, and no liraglutide half-life figure appears in the label text sourced here. What the labels do show is a dosing-frequency contrast: Saxenda is injected once daily [5], while Wegovy injection and Zepbound are injected once weekly [2] [4].
Because the labels are silent, the timing of the last liraglutide dose relative to the first weekly dose is left to the clinician [2] [3] [4] [5]. Anyone planning a switch can ask their prescriber directly when to take the final daily injection and when to give the first weekly one, rather than assuming a standard gap exists.
What does the switch study show?
A prospective study has examined a direct switch. Researchers followed adults with type 2 diabetes who had been on a stable GLP-1 receptor agonist dose for at least 3 months and switched them directly to tirzepatide 5 mg — skipping the 2.5 mg starting step the Zepbound label calls for [4] [6].
To enter, participants had to be at least 18 years old, have an HbA1c between 6.5% and 9.0%, and have a BMI of at least 25 kg/m² [6]. Allowed baseline GLP-1 drugs were daily liraglutide at 1.2 or 1.8 mg, weekly semaglutide at 0.5, 1.0, or 2.0 mg, or weekly dulaglutide at 0.75, 1.5, 3.0, or 4.5 mg [6]. Notably, liraglutide users were a small minority: 55% of participants were on semaglutide and 42% on dulaglutide at baseline [6]. The average participant was 58.3 years old with an HbA1c of 7.39%, a BMI of 35.18 kg/m², about 12.4 years of type 2 diabetes, and 55% were female [6].
At week 12, mean HbA1c fell by 0.43%, fasting serum glucose fell by 7.83 mg/dL, and body weight fell by 2.15 kg, all statistically significant [6]. On safety, 20 participants (13.2%) developed gastrointestinal events and 3 (2%) discontinued tirzepatide because of adverse events; there were no severe hypoglycemic events and no deaths [6].
This study has real limits. It included only people with type 2 diabetes, and its primary endpoint was HbA1c change at 12 weeks, not weight [6]. Several authors were employees and shareholders of Eli Lilly, the maker of Zepbound, and others reported Lilly consultancy fees [6]. Most importantly, the Zepbound label still directs a 2.5 mg once-weekly starting dose for 4 weeks [4], so a direct start at 5 mg is not label-endorsed practice. It is one study’s finding, not a dosing instruction.
Will I regain weight in the gap between prescriptions?
The closest evidence comes from the SCALE Obesity and Prediabetes trial, a 3-year Novo Nordisk-funded study of liraglutide 3.0 mg daily versus placebo in 2,254 adults with prediabetes, randomized 2:1 (1,505 on liraglutide, 749 on placebo) across 191 sites in 27 countries between June 1, 2011 and March 2, 2015 [7].
At week 160, the liraglutide group had lost an average of 6.1% of body weight versus 1.9% for placebo, an estimated treatment difference of −4.3% (95% CI −4.9 to −3.7, p<0.0001) [7]. Liraglutide also delayed type 2 diabetes onset: 26 of 1,472 (2%) liraglutide users were diagnosed with diabetes on treatment by week 160 versus 46 of 738 (6%) of placebo users, a hazard ratio of 0.21 (95% CI 0.13–0.34), with time to onset 2.7 times longer [7]. Serious adverse events occurred in 15% of the liraglutide group versus 13% of the placebo group [7].
Two cautions apply. Only 1,128 participants (50%) completed the study to week 160 — 714 (47%) withdrew from the liraglutide group and 412 (55%) from placebo [7]. And the authors themselves state that withdrawn individuals were not followed after discontinuation [7], so the trial says nothing about weight trajectories after stopping the drug. Whether a days-long gap between prescriptions causes regain is a question these studies do not answer.
Which side effects and warnings carry over to the new drug?
The common adverse-reaction lists in the labels overlap. Nausea, diarrhea, constipation, vomiting, injection site reactions, dyspepsia, fatigue, and abdominal pain all appear on both the Saxenda list and the Zepbound list of reactions reported in at least 5% of patients [4] [5]. Saxenda’s list also includes headache, hypoglycemia, dizziness, and increased lipase [5]; Zepbound’s also includes hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease [4]. Whether any individual’s nausea is better or worse on the new drug is not something these labels answer.
Several warnings apply to all of these drugs:
- Boxed warning on thyroid C-cell tumors. All three injection labels carry a boxed warning about thyroid C-cell tumors, though each states the animal evidence differently: Wegovy’s label says semaglutide causes thyroid C-cell tumors in rodents [2], Zepbound’s says tirzepatide causes them in rats [4], and Saxenda’s says liraglutide causes them in both rats and mice [5]. All three state it is unknown whether the drug causes these tumors in humans, and all are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [2] [4] [5].
- Hypoglycemia with insulin or insulin secretagogues. The Saxenda, Zepbound, and oral semaglutide labels flag increased hypoglycemia risk when combined with insulin or an insulin secretagogue such as a sulfonylurea, and note that reducing the dose of those drugs may be necessary [3] [4] [5]. Wegovy’s label directs monitoring blood glucose before and during treatment in patients with diabetes [2].
- Severe gastroparesis. Wegovy, Zepbound, Saxenda, and oral semaglutide are all not recommended in patients with severe gastroparesis [2] [3] [4] [5].
- Anesthesia aspiration risk. Pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists undergoing elective procedures; the Zepbound and Saxenda labels instruct patients to tell healthcare providers about planned surgeries or procedures [4] [5].
- Delayed gastric emptying. Zepbound and Saxenda delay gastric emptying and may affect absorption of other oral medications [4] [5].
Which weekly drug fits which indication?
Indication differences may matter more than dose when choosing what to switch to. Wegovy injection is indicated for cardiovascular risk reduction in adults with established cardiovascular disease plus obesity or overweight; for weight reduction in adults and patients 12 and older with obesity, or adults with overweight plus at least one comorbidity; and for noncirrhotic MASH with F2–F3 fibrosis under accelerated approval [2]. Zepbound is indicated for weight reduction and long-term maintenance in adults with obesity or overweight plus a comorbidity, and for moderate-to-severe obstructive sleep apnea in adults with obesity [4]. Oral semaglutide (Rybelsus and Ozempic tablets) is indicated for glycemic control in adults with type 2 diabetes and for reducing major adverse cardiovascular event risk in adults with type 2 diabetes at high risk [3]. Saxenda’s indications cover adults and patients 12 and older weighing more than 60 kg with obesity, and adults with overweight plus a weight-related comorbidity [5].
Someone switching from Saxenda for weight management is not necessarily a match for a diabetes-indicated drug, and vice versa. That matching is part of the prescriber conversation.
What should I ask my prescriber before switching?
The labels leave several practical decisions entirely to the clinician: when to take the last liraglutide dose relative to the first weekly dose, how fast to escalate, and whether insulin or sulfonylurea doses need adjusting [2] [3] [4] [5]. The Zepbound label adds that prescribers should consider treatment response and tolerability when selecting the maintenance dosage [4].
Reasonable questions to bring to the appointment include: What date should the last daily injection be? What date should the first weekly injection be? Which starting dose and escalation schedule is being prescribed, and why? If insulin or a sulfonylurea is part of the regimen, does its dose change? What side effects warrant a call before the next scheduled dose?
For context on how one label handles intolerance during escalation, the Saxenda label includes a pediatric provision: pediatric patients who do not tolerate an increased dose may have the dose lowered back to the previous level, escalation may take up to 8 weeks, and patients who do not tolerate 3 mg daily may be reduced to 2.4 mg daily [5]. That provision is specific to liraglutide and to pediatric patients in the Saxenda label; the weekly-drug labels here contain no comparable tolerance language.
Finally, anyone with a planned surgery or procedure should mention the GLP-1 medication to the anesthesia team, per the aspiration warnings on the Zepbound and Saxenda labels [4] [5].
This page describes what FDA labeling and published studies state. It is not medical advice, and no one should start, stop, skip, or time a dose based on it alone — those decisions belong with a prescriber who knows the full medical history.
Sources
- JAMA. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- DailyMed. WEGOVY- semaglutide injection, solution; WEGOVY- semaglutide tablet.
- DailyMed. OZEMPIC- oral semaglutide tablet; RYBELSUS- oral semaglutide tablet.
- DailyMed. ZEPBOUND- tirzepatide injection, solution; ZEPBOUND KWIKPEN- tirzepatide injection, solution.
- DailyMed. SAXENDA- liraglutide injection, solution. February 25, 2026.
- PubMed. Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.
- PubMed. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
- PubMed. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
- US Food and Drug Administration. Drug shortage information for liraglutide injection.
- PMC. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026.
- DailyMed. VICTOZA- liraglutide injection. October 14, 2025.
Frequently asked questions
Is Saxenda 3 mg equal to any specific Wegovy dose?
No. No conversion or dose-equivalence table between liraglutide and semaglutide appears in the Wegovy, Zepbound, oral semaglutide, or Saxenda labels. Wegovy dosing runs on its own schedule, starting at 0.25 mg once weekly for 4 weeks with a usual maintenance dose of 2.4 mg once weekly. Any mg-to-mg equivalence claim is not from those labels.
Do I start Wegovy at 0.25 mg even though I was already on liraglutide?
The Wegovy label's dosage section gives one starting dose — 0.25 mg once weekly for 4 weeks — and provides no alternate starting dose for patients previously on another GLP-1 receptor agonist. The label does not vary its starting dose by prior treatment, so the dose an individual actually begins at is a prescriber decision.
Can I take my last liraglutide dose and the first weekly dose in the same week?
The labels advise against using these drugs together. Saxenda, Wegovy, and Zepbound each state that coadministration with any other GLP-1 receptor agonist is not recommended. No washout interval appears in those labels, so the exact timing of the last daily dose and first weekly dose is a prescriber decision.
How long does titration take on the weekly drug?
Wegovy injection starts at 0.25 mg once weekly for 4 weeks and titrates every 4 weeks per the label's escalation schedule toward the usual 2.4 mg weekly maintenance dose. Zepbound starts at 2.5 mg weekly for 4 weeks and increases in 2.5 mg increments after at least 4 weeks, up to a maximum of 15 mg weekly.
Can I skip Zepbound 2.5 mg and start at 5 mg?
The Zepbound label directs a 2.5 mg once-weekly starting dose for 4 weeks. One prospective study switched adults with type 2 diabetes directly from GLP-1 receptor agonists to tirzepatide 5 mg and reported acceptable tolerability over 12 weeks, but that study was Lilly-affiliated, diabetes-only, and does not change the label. Skipping the starting dose is not label-endorsed.
Will I regain weight in the gap between the two prescriptions?
In the 3-year SCALE trial, liraglutide 3.0 mg produced −6.1% body weight versus −1.9% for placebo at week 160, but the authors state that people who withdrew were not followed after discontinuation, so the trial says nothing about weight after stopping.
Does the new weekly drug cause worse nausea than liraglutide?
Nausea, diarrhea, vomiting, and constipation appear on both the Saxenda and Zepbound common adverse reaction lists, so similar gastrointestinal effects are possible on either drug. The labels do not compare nausea rates between the two, and how any one person tolerates a switch is individual.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.